Citadel Advisors’s Transphorm, Inc. Common Stock TGAN Stock Holding History

Citadel Advisors’s Portfolio TGAN Stock Details TGAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-43,286	Closed	-$213K	–	15759
2024 Q1	$213K	Buy	+43,286	New	+$205K	﹤0.01%	10186
2022 Q2	–	Sell	-54,397	Closed	-$385K	–	14424
2022 Q1	$385K	Buy	+54,397	New	+$382K	﹤0.01%	10009

Citadel Advisors's TGAN Position: Q2 2024 in Review

Citadel Advisors sold out of Transphorm, Inc. Common Stock (TGAN) in Q2 2024, closing a stake of 43,286 shares — an estimated $213K sold.

Citadel Advisors first reported a position in TGAN in Q1 2022 and held it in 2 quarters. The position peaked at $385K in Q1 2022. 0 funds tracked by Wall St. Rank hold TGAN as of Q2 2024.

Citadel Advisors reported no remaining Transphorm, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Citadel Advisors sold 43,286 Transphorm, Inc. Common Stock shares in Q2 2024, an estimated $213K.
Citadel Advisors first reported a position in Transphorm, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
Citadel Advisors's Transphorm, Inc. Common Stock position peaked at $385K in Q1 2022.
0 funds tracked by Wall St. Rank held Transphorm, Inc. Common Stock as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.